Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


ProFibrix to enter in a research collaboration with Bioceros

Leiden and Utrecht, The Netherlands – April 2, 2007 -- ProFibrix BV and Bioceros BV today announced that they have entered into a research collaboration. Bioceros will employ its expertise, experience and know-how in generating and testing new proteins to assist ProFibrix with its R & D programs. The research collaboration is focused on establishing a dedicated platform for production, purification and characterization of fibrinogen.

Financial terms of the collaboration were not disclosed.

“We are impressed by the know-how of the employees and by the facilities of Bioceros. We expect that this collaboration will significantly accelerate our early stage development programs, while we stay focused on the development of our lead product FibrocapsTM”, stated Dr. Jaap Koopman, CEO of ProFibrix.

Remco Brandt, CEO of Bioceros, comments: “We are pleased to be working with ProFibrix. This project fits perfectly in our current strategy to increase our CRO activities in the field of protein production and characterization. It also clearly demonstrates the demand for experienced R&D service providers like Bioceros by small Venture Capital backed companies that like to stay lean and flexible during the first years of development.”

About ProFibrix BV
ProFibrix aims to create, develop and market new and innovative healthcare products, based on the unique properties of human fibrinogen. The lead product is FibrocapsTM a dry powder fibrin sealant that is expected to enter clinical development in the 2nd half of 2008. The company is also establishing a fibrinogen technology platform that carefully analyzes the structure and function of fibrinogen variants, identifies the most promising therapeutic targets and then develops the most suitable formulation for each application.

About Bioceros BV
Bioceros is headquartered in Utrecht, the Netherlands and founded in 2003. The company is a contract research organization with a focus on collaborative research with other biotechnology companies, pharmaceutical enterprises and academic institutions in the field of immunology, specifically auto-immune diseases, oncology and infectious diseases. In addition the Company provides cell line generation and pilot production services at pre-clinical scale.

For further information, visit or or contact:
ProFibrix BV:
Jaap Koopman, Ph.D. (CEO)
Acacialaan 7
2351 CA Leiderdorp
The Netherlands
tel. +31 (0) 6-21628475

Bioceros BV:
Remco M. Brandt, M.Sc. (CEO)
Yalelaan 46
3584 CM Utrecht
The Netherlands
tel. +31 (0) 30-253 7910

Publisher Contact Information:

Bioceros BV
+31 (0)30 253 7910

Company profile of Bioceros (acquired by Epirus)
Past press releases of Bioceros (acquired by Epirus).


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Oct 11N/AInternet services
Oct 11€1.1MKnowledge management
Oct 11N/AInternet services
Oct 11€13.0MBiotechnology
Oct 11N/AMedical devices
Oct 10€50.0MInternet services
Oct 10€23.0MOther Computers & Electronics

For information on Europe's most extensive database on technology funding click here!


Press Releases

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.